Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent fasting vs semaglutide for weight loss in overweight and obese adults
ChiCTR2300073923Phase 4Not yet recruiting
- Sponsor
- Shanghai Tongren Hospital
- Start
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide in obesity (2 arms), sponsored by Shanghai Tongren Hospital. Primary endpoints: Weight loss rate during intervention period and Weight change rate during drug withdrawal observation period. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on ChiCTR2300073923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073923.